Ralliant (NYSE:RAL) Downgraded to Buy Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Ralliant from “strong buy” to “buy,” although the broader analyst consensus remains “Moderate Buy” with a $75.70 price target.
• Ralliant reported quarterly EPS of $0.68, exceeding the $0.63 consensus estimate, on revenue of $567.8 million. Management issued fiscal 2026 EPS guidance of $2.76–$2.90.
• The stock opened at $61.65, down 2.6%, while CEO Tamara S. Newcombe and SVP Karen M. Bick sold shares under pre-arranged Rule 10b5-1 trading plans.

Ralliant (NYSE:RAL - Get Free Report) was downgraded by Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued on Sunday.

A number of other research analysts have also issued reports on RAL. Oppenheimer boosted their price target on shares of Ralliant from $50.00 to $65.00 and gave the stock an "outperform" rating in a research note on Wednesday, May 13th. Weiss Ratings restated a "sell (d)" rating on shares of Ralliant in a research report on Friday, July 31st. Morgan Stanley lifted their price objective on Ralliant from $68.00 to $85.00 and gave the company an "overweight" rating in a report on Tuesday, June 23rd. Zacks Research upgraded Ralliant from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, June 30th. Finally, Royal Bank Of Canada increased their target price on Ralliant from $71.00 to $73.00 and gave the stock a "sector perform" rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $75.70.

Ralliant Stock Down 2.6%

RAL opened at $61.65 on Friday. Ralliant has a twelve month low of $37.27 and a twelve month high of $75.41. The company has a market cap of $6.82 billion, a PE ratio of -5.68, a price-to-earnings-growth ratio of 2.29 and a beta of 1.60. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. The company has a 50-day moving average price of $68.40 and a 200 day moving average price of $56.42.

Ralliant (NYSE:RAL - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.63 by $0.05. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. The business had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Sell-side analysts expect that Ralliant will post 2.87 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Tamara S. Newcombe sold 12,936 shares of the business's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $71.79, for a total value of $928,675.44. Following the completion of the transaction, the chief executive officer owned 251,967 shares of the company's stock, valued at $18,088,710.93. The trade was a 4.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karen M. Bick sold 6,062 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $72.00, for a total value of $436,464.00. Following the completion of the transaction, the senior vice president owned 31,668 shares of the company's stock, valued at $2,280,096. This trade represents a 16.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.42% of the company's stock.

Hedge Funds Weigh In On Ralliant

Several hedge funds and other institutional investors have recently modified their holdings of the company. Cetera Investment Advisers acquired a new position in shares of Ralliant during the second quarter worth about $700,000. Russell Investments Group Ltd. purchased a new stake in shares of Ralliant during the 2nd quarter valued at about $1,465,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Ralliant during the 2nd quarter valued at about $39,000. First Trust Advisors LP purchased a new stake in shares of Ralliant during the 2nd quarter valued at about $2,013,000. Finally, Federated Hermes Inc. acquired a new position in Ralliant during the 2nd quarter worth approximately $326,000.

About Ralliant

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source